{"filing":{"accession_number":"0001213900-26-079808","cik":"0001611842","ticker":"PYPD","company_name":"PolyPid Ltd.","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"ea0298559-6k_polypid.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea0298559-6k_polypid.htm"},"events":[{"id":18962,"run_id":17062,"accession_number":"0001213900-26-079808","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"PolyPid has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for D-PLEX100 commercialization in the U.S. and Canada. The agreement involves substantial financial consideration ($30 million upfront and near-term, plus up to $300 million in milestone payments and tiered royalties), transfer of commercial rights, and manufacturing obligations. This constitutes a material disposition of commercial rights and a significant strategic transaction that would affect a reasonable investor's assessment of the company's value and future revenue streams.","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":17927,"accession_number":"0001213900-26-079808","item_number":"EX-99.1","item_title":"ea029855901ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"PolyPid has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for D-PLEX100 commercialization in the U.S. and Canada. The agreement involves substantial financial consideration ($30 million upfront and near-term, plus up to $300 million in milestone payments and tiered royalties), transfer of commercial rights, and manufacturing obligations. This constitutes a material disposition of commercial rights and a significant strategic transaction that would affect a reasonable investor's assessment of the company's value and future revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:35:37.195829+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17927,"accession_number":"0001213900-26-079808","item_number":"EX-99.1","item_title":"ea029855901ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"PolyPid has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for D-PLEX100 commercialization in the U.S. and Canada. The agreement involves substantial financial consideration ($30 million upfront and near-term, plus up to $300 million in milestone payments and tiered royalties), transfer of commercial rights, and manufacturing obligations. This constitutes a material disposition of commercial rights and a significant strategic transaction that would affect a reasonable investor's assessment of the company's value and future revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:35:37.195829+00:00","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-07-21"}]}